Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells

Jakubowska-Mućka,Anna; Sieńko,Jacek; Zapała,Łukasz; Wolny,Rafał; Lasek,Witold

doi:10.3892/or.2012.1639

Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells

Authors:
- Anna Jakubowska-Mućka
- Jacek Sieńko
- Łukasz Zapała
- Rafał Wolny
- Witold Lasek
View Affiliations

Affiliations: Department of Immunology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1a Street, F building, 02-097 Warsaw, Poland
Published online on: January 16, 2012 https://doi.org/10.3892/or.2012.1639
Pages: 1245-1250

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sulindac, a non-steroidal anti-inflammatory drug, suppresses carcinogenesis and inhibits growth of tumor cells. Pyrrolidine dithiocarbamate (PDTC), a potent NF-κB inhibitor, has been also identified as a potential anti-neoplastic agent. We hypothesized that combination of sulindac and PDTC could result in augmentation of cytotoxicity against ovarian cancer cells. The effect of sulindac and PDTC was examined on several ovarian cancer lines. Tumor cell viability was assessed using the MTT assay. Annexin-V/PI staining was used to detect apoptosis, cell cycle distribution was analyzed in FACS, and expression of cellular proteins was detected by western blotting. Incubation of OVA-14, OVP-10 and CAOV-1 ovarian cancer cells with sulindac and PDTC resulted in significantly greater inhibition of cell viability compared to either compound alone. In a model of OVA-14 cells it was evident that this effect was not related to the expression of COX enzymes since both active (sulindac sulfide) and inactive (sulindac) in vitro compounds affected the growth of tumor cells to a similar extent and synergized in cytotoxicity with PDTC. Combination of sulindac and PDTC lead to G0 arrest and massive apoptosis in co-treated cultures. Western blotting analysis argued for induction of the mitochondrial apoptotic pathway. These data demonstrate the synergistic cytotoxic effect of sulindac and PDTC on ovarian cancer cells through apoptosis and cell cycle arrest and prompt to test the efficacy of this combination in animal models.

View Figures

View References

1	Gubbels JAA, Claussen N, Kapur AK, Connor JP and Patankar MS: The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res. 3:8–11. 2010. View Article : Google Scholar : PubMed/NCBI
2	Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Tisseron Carrasco A and Lhomme C: Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol. 116:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
3	Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G, Xiros N and Economopoulos T: Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel-pretreated ovarian carcinoma. Gynecol Oncol. 118:52–57. 2010. View Article : Google Scholar
4	Ledermann JA and Raja FA: Targeted trials in ovarian cancer. Gynecol Oncol. 119:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
5	Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C and Meyskens F: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
6	Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL and Shore RE: Aspirin and epithelial ovarian cancer. Prev Med. 33:682–687. 2001. View Article : Google Scholar : PubMed/NCBI
7	Sporn MB and Hong WK: Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nat Clin Pract Oncol. 5:628–629. 2008. View Article : Google Scholar : PubMed/NCBI
8	Verheul HMW, Panigrahy D, Yuan J and D’Amato RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer. 79:114–118. 1999. View Article : Google Scholar : PubMed/NCBI
9	Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS and Munkarah A: Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 126:382–394. 2010. View Article : Google Scholar : PubMed/NCBI
10	Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE and Grizzle WE: Effects of non-steroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 8:202–209. 2002.
11	Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic factor production in ovarian cancer. Cancer Res. 63:906–911. 2003.PubMed/NCBI
12	Munkarah A and Ali-Fehmi R: COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol. 17:49–53. 2005. View Article : Google Scholar : PubMed/NCBI
13	Andrews P, Zhao X, Allen J, Li F and Chang M: A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 61:203–214. 2008. View Article : Google Scholar : PubMed/NCBI
14	Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ and Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 6:1736–1744. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kunte DP, Wali RK, Koetsier JL and Roy HK: Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol Cancer Ther. 7:1797–1806. 2008. View Article : Google Scholar : PubMed/NCBI
16	Marotta A, Parhar K, Hundal R, Duronio V and Salh B: Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide. Int J Oncol. 28:1471–1479. 2006.PubMed/NCBI
17	Karl T, Seibert N, Stohr M, Osswald H, Rosl F and Finzer P: Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 245:103–111. 2007. View Article : Google Scholar : PubMed/NCBI
18	Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH and Yang W: JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 560:95–100. 2007. View Article : Google Scholar : PubMed/NCBI
19	Kim JS, Baek SJ, Sali T and Eling TE: The conventional non-steroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 4:487–493. 2005.PubMed/NCBI
20	Nikitakis NG, Hebert C, Lopes MA, Reynolds MA and Sauk JJ: PPARγ-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 98:817–823. 2002.
21	Park JH, Kim EJ, Jang HY, Shim H, Lee KK, Jo HJ, Kim HJ, Yang SH, Jeong ET and Kim HR: Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 20:379–384. 2008.PubMed/NCBI
22	Flis S and Spławiński J: Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res. 29:435–442. 2009.PubMed/NCBI
23	Barnes AP, Miller BE and Kucera GL: Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol. 104:443–450. 2007. View Article : Google Scholar : PubMed/NCBI
24	Govindan R, Wang X, Baggstrom MQ, Burdette-Radoux S, Hodgson L, Vokes EE and Green MR; Cancer and Leukemia Group B. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 3014. J Thorac Oncol. 4:220–226. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD and Zahurak M: Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma. Am J Clin Oncol. 29:395–398. 2006. View Article : Google Scholar : PubMed/NCBI
26	Oh DH, Bang JS, Choi HM, Yang HI, Yoo MC and Kim KS: Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells. Eur J Pharmacol. 649:135–139. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chen D, Peng F, Cui QC, Danie KG, Orlu S, Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosc. 10:2932–2939. 2005. View Article : Google Scholar
28	Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD and Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21W^AF1/CIP1 via C/EBPβ. Nat Med. 3:1233–1241. 1997. View Article : Google Scholar : PubMed/NCBI
29	Morais C, Gobe G, Johnson DW and Healy H: Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis. 14:412–425. 2010. View Article : Google Scholar
30	Liu GH, Wang SR, Wang B and Kong BH: Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer. 16:1777–1782. 2006.
31	Gu JW, Young E, Busby B, Covington J, Tan W and Johnson JW: Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis and growth of breast cancer in female mice. Cancer Biol Ther. 8:514–521. 2009. View Article : Google Scholar : PubMed/NCBI
32	Jakubowska-Mucka A, Sienko J, Switaj T, Golab J and Lasek W: Antitumor effects of sulindac in ovarian cancer cell cultures. Ginekol Pol. 82:195–199. 2011.(In Polish).
33	Chou TC and Talalay P: Quantitive analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
34	Seo AM, Hong SW, Shin JS, Park IC, Hong NJ, Kim DJ, Lee WK, Lee WJ, Jin DH and Lee MS: Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKβ. Apoptosis. 14:913–922. 2009.PubMed/NCBI
35	Yamamoto Y, Yin MJ, Lin KM and Gaynor RB: Sulindac inhibition activation of the NF-κB pathway. J Biol Chem. 274:27307–27314. 1999.
36	Nakanishi C and Toi M: Nuclear factor κB inhibitors as sensitizers to anticancer drugs. Nature Rev Cancer. 5:297–309. 2005.
37	Nai YJ, Jiang ZW, Wang ZM, Li N and Li JS: Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice. JPEN J Parenter Enteral Nutr. 31:18–25. 2007. View Article : Google Scholar : PubMed/NCBI
38	O’Connor R, O’Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O’Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M and Crown J: A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 59:79–87. 2007.PubMed/NCBI
39	Moos PJ, Muskardin DT and Fitzpatrick FA: Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol. 162:467–473. 1999.PubMed/NCBI
40	Morais C, Gobe G, Johnson DW and Healy H: Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis. 12:365–379. 2009. View Article : Google Scholar : PubMed/NCBI